CJC 1295 + Ipamorelin 10MG

CJC‑1295 + Ipamorelin is a common peptide combo used to increase endogenous growth hormone (GH) secretion by stimulating the pituitary. Below is a concise, practical summary of benefits, mechanisms, common uses, typical dosing approaches, and safety points. Use only under medical supervision.

What they are and how they work

• CJC‑1295: a GHRH analog that raises GH release and (depending on formulation) can prolong GH pulses. Two forms exist: with DAC (drug‑affinity complex) — longer half‑life (weekly dosing); without DAC (also called GRF‑1‑29) — short acting (multiple daily injections).
• Ipamorelin: a selective ghrelin/GHSR agonist (a growth‑hormone secretagogue) that increases amplitude of GH pulses with minimal effect on cortisol or prolactin.
• Combined: synergistic — CJC‑1295 improves pulse initiation; ipamorelin increases pulse amplitude/frequency → greater physiologic GH/IGF‑1 release than either alone.

Reported benefits / clinical uses

• Increased lean muscle mass and improved body composition (reduced fat).
• Enhanced recovery from exercise, injury and surgery (improved tissue repair).
• Improved sleep quality (more deep sleep due to increased nocturnal GH).
• Better energy, stamina and exercise capacity.
• Improved skin tone, collagen production and wound healing.
• Support for age‑related declines in GH (anti‑aging/functional optimization).
• May aid bone density maintenance and metabolic health via IGF‑1 effects.

Typical administration & dosing patterns (examples used in clinics; non‑prescriptive)

• Route: subcutaneous injections (abdomen, thigh); some use intramuscular for specific protocols.
• Session timing: many users inject pre‑bed (to leverage nocturnal GH pulse) and/or post‑workout, or distribute doses throughout the day (2–3x).
• Common example protocols:

  • CJC‑1295 (no DAC / GRF‑1‑29): 100 mcg once to twice daily.
  • Ipamorelin: 100–300 mcg per injection, 2–3 times daily (total daily 300–900 mcg).
  • CJC‑1295 with DAC: 1–2 mg once weekly (if using DAC form) + ipamorelin injections daily as above.
• A “10 mg” vial label usually refers to total peptide in the vial prior to reconstitution — actual per‑injection dose is mcg level and set by dilution and protocol.

Typical cycle length

• Many protocols run 8–12 weeks followed by reassessment; some longer‑term maintenance regimens exist depending on goals and medical oversight.

Expected timeline for effects

• Sleep and some recovery improvements: days–weeks.
• Noticeable changes in body composition and strength: 6–12+ weeks.